Back
  1. Home
  2. Profile of Muriel HANNON (ULiège)
Profil

HANNON Muriel

Unilab > Unité de laboratoire - endocrino - métabolique

See author's contact details
Main Referenced Co-authors
Baron, Frédéric  (79)
Beguin, Yves  (78)
Ehx, Grégory  (37)
Belle, Ludovic  (34)
Humblet-Baron, Stéphanie (31)
Main Referenced Keywords
GVHD (19); Th17 (9); NSG (5); NSG mice (5); Rapamycin (5);
Main Referenced Unit & Research Centers
GIGA-I3 - Giga-Infection, Immunity and Inflammation - ULiège [BE] (16)
Giga-Infection, Immunity and Inflammation Laboratoire d'hématologie (8)
Giga-Haematology (1)
Hematologie CHU- GIGA-R (1)
Main Referenced Disciplines
Hematology (62)
Biochemistry, biophysics & molecular biology (13)
Immunology & infectious disease (6)
Surgery (2)
Gastroenterology & hepatology (1)

Publications (total 83)

The most downloaded
2294 downloads
Castermans, E., Hannon, M., Drion, P., Geenen, V., Beguin, Y., & Baron, F. (2009). Reconstitution du système immunitaire après allogreffe de cellules souches hématopoïétiques. Revue Médicale de Liège, 64 (S1), 2-8. https://hdl.handle.net/2268/34992

The most cited

109 citations (Scopus®)

Cuende, J., Liénart, S., Dedobbeleer, O., van der Woning, B., De Boeck, G., Stockis, J., Huygens, C., Colau, D., SOMJA, J., Delvenne, P., Hannon, M., Baron, F., Dumoutier, L., Renauld, J.-C., De Haard, H., Saunders, M., Coulie, P., & Lucas, S. (2015). Monoclonal antibodies against GARP/TGF-β1 complexes inhibit the immunosuppressive activity of human regulatory T cells in vivo. Science Translational Medicine, 7, 284ra56. doi:10.1126/scitranslmed.aaa1983 https://hdl.handle.net/2268/183672

Harvengt, J., & Hannon, M. (2023). Genetics of severe early-onset obesity: diagnosis of monogenic etiologies as a new paradigm and challenge in the era of new anti-obesity therapies. Tempo Médical.
Editorial reviewed

Ehx, G.* , Ritacco, C.* , HANNON, M., DUBOIS, S., Delens, L., WILLEMS, E., SERVAIS, S., Drion, P., BEGUIN, Y., & Baron, F. (2021). Comprehensive analysis of the immunomodulatory effects of rapamycin on human T cells in graft-versus-host disease prophylaxis. American Journal of Transplantation, 21, 2662-2674. doi:10.1111/ajt.16505
Peer Reviewed verified by ORBi
* These authors have contributed equally to this work.

Delens, L., Ehx, G., SOMJA, J., Vrancken, L., Belle, L., SEIDEL, L., Grégoire, C., Fransolet, G., Ritacco, C., Hannon, M., DUBOIS, S., Beguin, Y., Baron, F., & Servais, S. (2019). In Vitro Th17-Polarized Human CD4(+) T Cells Exacerbate Xenogeneic Graft-versus-Host Disease. Biology of Blood and Marrow Transplantation, 25, 204-215. doi:10.1016/j.bbmt.2018.10.007
Peer Reviewed verified by ORBi

Grégoire, C., Ritacco, C., Hannon, M., SEIDEL, L., Delens, L., Belle, L., DUBOIS, S., Veriter, S., LECHANTEUR, C., BRIQUET, A., Servais, S., Ehx, G., Beguin, Y., & Baron, F. (2019). Comparison of Mesenchymal Stromal Cells From Different Origins for the Treatment of Graft-vs.-Host-Disease in a Humanized Mouse Model. Frontiers in Immunology, 10, 619. doi:10.3389/fimmu.2019.00619
Peer Reviewed verified by ORBi

Ehx, G., SOMJA, J., Warnatz, H.-J., Ritacco, C., HANNON, M., Delens, L., Fransolet, G., DELVENNE, P., Muller, J., BEGUIN, Y., Lehrach, H., Belle, L., Humblet-Baron, S., & BARON, F. (2018). Xenogeneic graft-versus-host disease in humanized NSG and NSG-HLA-A2/HHD mice. Frontiers in Immunology, 9, 1943. doi:10.3389/fimmu.2018.01943
Peer Reviewed verified by ORBi

DETRY, O., VANDERMEULEN, M., DELBOUILLE, M.-H., SOMJA, J., BLETARD, N., Briquet, A., LECHANTEUR, C., GIET, O., BAUDOUX, E., Hannon, M., Baron, F., & Beguin, Y. (July 2017). Infusion of mesenchymal stromal cells after deceased liver transplantation: A phase I-II, open-label, clinical study. Journal of Hepatology, 67 (1), 47-55. doi:10.1016/j.jhep.2017.03.001
Peer Reviewed verified by ORBi

Delens, L., SERVAIS, S., Ehx, G., Vrancken, L., Fransolet, G., GREGOIRE, C., Hannon, M., DUBOIS, S., Daulne, C., BEGUIN, F., & BARON, F. (24 May 2017). Th17 cells impact on xenogeneic graft-versus-host disease [Poster presentation]. 2017 Immunology day FNRS-Immunology Doctoral School, Gosselies, Belgium.

Delens, L., SERVAIS, S., Vrancken, L., Ehx, G., Fransolet, G., Hannon, M., DUBOIS, S., Daulne, C., Beguin, Y., & Baron, F. (27 March 2017). Xenogeneic graft-versus-host disease : Impact of Th17 cells [Poster presentation]. 43rd Annual Meeting of the European Society for Blood and Marrow Transplantation, Marseille, France.

Ehx, G., Hannon, M., DUBOIS, S., Daulne, C., Drion, P., BEGUIN, Y., Humblet-Baron, S., & BARON, F. (March 2017). Immunomodulatory effects of rapamycin in xenogeneic Graft versus Host Disease. Biology of Blood and Marrow Transplantation, 23 (3), 365–S366. doi:10.1016/j.bbmt.2016.12.314
Peer Reviewed verified by ORBi

Ehx, G., SOMJA, J., Fransolet, G., Delens, L., Muller, J., BEGUIN, Y., Humblet-Baron, S., Hannon, M., & BARON, F. (10 February 2017). Comparison of xenogeneic graft-versus-host reactions in humanized NSG and NSG-HLA-A2/HHD mice [Poster presentation]. 32nd General Annual Meeting of the Belgian Hematological Society, Bruxelles, Belgium.

Ehx, G., HANNON, M., Dubois, S., Daulne, C., Drion, P., Beguin, Y., Humblet-Baron, S., & Baron, F. (10 February 2017). Immunomodulatory effects of rapamycin in xenogeneic Graft versus Host Disease. Journal of Clinical Immunology, 37 (2), 197-266. doi:10.1007/s10875-017-0372-z
Peer Reviewed verified by ORBi

Ehx, G., SOMJA, J., Delens, L., Fransolet, G., DELVENNE, P., Muller, J., BEGUIN, Y., Hannon, M., Humblet-Baron, S., & BARON, F. (01 February 2017). Comparison of xenogeneic graft-versus-host reactions in humanized NSG and NSG-HLA-A2/HHD mice [Paper presentation]. GIGA-Day 2017: New insights into the hallmark of cancer, Liège, Belgium.

Delens, L., SERVAIS, S., Vrancken, L., Ehx, G., Fransolet, G., Hannon, M., DUBOIS, S., Daulne, C., BEGUIN, Y., & BARON, F. (February 2017). Impact of Th17 population on xenogeneic graft-versus-host disease [Poster presentation]. 32nd General Annual Meeting of the Belgian Hematology Society, La Hulpe, Belgium.

DETRY, O., VANDERMEULEN, M., DELBOUILLE, M.-H., SOMJA, J., BLETARD, N., BRIQUET, A., LECHANTEUR, C., GIET, O., BAUDOUX, E., Hannon, M., Baron, F., & BEGUIN, Y. (January 2017). UNE INJECTION UNIQUE DE CELLULES STROMALES MESENCHYMATEUSES AU JOUR 3 APRES GREFFE HEPATIQUE EST INSUFFISANTE POUR INDUIRE UNE TOLERANCE OPERATIONNELLE. Transplant International, 30 (suppl 1), 8 (O12.
Peer Reviewed verified by ORBi

SERVAIS, S., Hannon, M., Peffault de Latour, R., Socie, G., & BEGUIN, Y. (2017). Reconstitution of adaptive immunity after umbilical cord blood transplantation and clinical implication regarding risk of infections. Stem Cell Investigation, 4, 40.
Peer Reviewed verified by ORBi

Ehx, G., Fransolet, G., De Leval, L., D'Hondt, S., Lucas, S., Hannon, M., Delens, L., DUBOIS, S., Drion, P., Beguin, Y., Humblet-Baron, S., & Baron, F. (2017). Azacytidine prevents experimental xenogeneic graft-versus-host disease without abrogating graft-versus-leukemia effects. Oncoimmunology, 6:e1314425. doi:10.1080/2162402X.2017.1314425
Peer Reviewed verified by ORBi

Belle, L.* , Fransolet, G.* , Somja, J., BINSFELD, M., Delvenne, P., Drion, P., Hannon, M., BEGUIN, Y., Ehx, G.* , & Baron, F.*. (12 December 2016). Limited Impact of Imatinib in a Murine Model of Sclerodermatous Chronic Graft-versus-Host Disease. PLoS ONE, 11, 0167997. doi:10.1371/journal.pone.0167997
Peer Reviewed verified by ORBi
* These authors have contributed equally to this work.

Delens, L., SERVAIS, S., Vrancken, L., Ehx, G., Fransolet, G., Hannon, M., DUBOIS, S., Daulne, C., BEGUIN, Y., & Baron, F. (08 December 2016). Xenogeneic graft-versus-host disease: Impact of Th17 cells [Poster presentation]. Journée des chercheurs Télévie 2017, Bruxelles, Belgium.

Fransolet, G., Belle, L., SOMJA, J., DELVENNE, P., Hannon, M., Drion, P., BINSFELD, M., BEGUIN, Y., Ehx, G., & Baron, F. (08 December 2016). Limited impact of imatinib in a murine model of sclerodermatous chronic graft-versus-host disease (scl-cGVHD) [Paper presentation]. Séminaire des chercheurs Télévie 2017, Bruxelles, Belgium.

Ehx, G., Fransolet, G., de Leval, L., D'Hondt, S., Lucas, S., Hannon, M., Delens, L., DUBOIS, S., Drion, P., BEGUIN, Y., Humblet-Baron, S., & BARON, F. (18 November 2016). Azacytidine prevents experimental xenogeneic graft-versus-host disease without abrogating graft-versus-leukemia effects [Paper presentation]. Congrès Commun de la SFGM-TC et de la SFBCT, Liège, Belgium.

Delens, L., SERVAIS, S., Ehx, G., Vrancken, L., Fransolet, G., GREGOIRE, C., Hannon, M., DUBOIS, S., Daulne, C., BEGUIN, Y., & BARON, F. (18 November 2016). Impact des cellules Th17 sur la GVH xénogénique [Paper presentation]. 16ème édition du congrès de la SFGM-TC, Société Francophone de Greffe de Moelle et de Thérapie Cellulaire, Liège, Belgium.

Belle, L., Fransolet, G., SOMJA, J., BINSFELD, M., DELVENNE, P., Drion, P., Hannon, M., BEGUIN, Y., Ehx, G., & Baron, F. (17 November 2016). Limited impact of imatinib in a murine model of sclerodermic chronic graft-versus-host disease [Poster presentation]. 16ème congrès de la Société Française de Greffe de Moelle et de Thérapie Cellulaire (SFGM-TC) en commun avec la SFBCT, Liège, Belgium.

Ehx, G., Fransolet, G., de Leval, L., D'Hondt, S., Lucas, S., Hannon, M., Delens, L., Drion, P., BEGUIN, Y., Humblet-Baron, S., & BARON, F. (14 October 2016). Azacytidine prevents experimental xenogeneic graft-versus-host disease without abrogating graft-versus-leukemia effects [Poster presentation]. Regulatory T cell mini-symposium, Leuven, Belgium.

Fransolet, G.* , Ehx, G.* , SOMJA, J., Delens, L., Hannon, M., Muller, J., DUBOIS, S., Drion, P., CAERS, J., Humblet-Baron, S., DELVENNE, P., BEGUIN, Y., Conteduca, G.* , & BARON, F.*. (04 July 2016). Azacytidine mitigates experimental sclerodermic chronic graft-versus-host disease. Journal of Hematology and Oncology, 9, 53. doi:10.1186/s13045-016-0281-2
Peer Reviewed verified by ORBi
* These authors have contributed equally to this work.

Delens, L., BEGUIN, Y., Vrancken, L., Ehx, G., Fransolet, G., Hannon, M., DUBOIS, S., Daulne, C., SERVAIS, S., & BARON, F. (27 May 2016). Th17 cell population seems to aggravate xenogeneic graft-versus-host disease [Poster presentation]. 2016 Immunology day FNRS-Immunology Doctoral School, Gosselies, Belgium.

SERVAIS, S., BEGUIN, Y., Delens, L., Ehx, G., Fransolet, G., Hannon, M., WILLEMS, E., Humblet-Baron, S., Belle, L., & Baron, F. (11 May 2016). Novel approaches for preventing acute graftversus- host disease after allogeneic hematopoietic stem cell transplantation. Expert Opinion on Investigational Drugs, 9, 957-972. doi:10.1080/13543784.2016.1182498
Peer Reviewed verified by ORBi

Ehx, G., Fransolet, G., de Leval, L., D'Hondt, S., Lucas, S., Hannon, M., Delens, L., DUBOIS, S., Drion, P., Beguin, Y., Humblet-Baron, S., & Baron, F. (March 2016). Azacytidine Enhances Regulatory T-Cells In Vivo and Prevents Experimental Xenogeneic Graft-Versus-Host Disease. Biology of Blood and Marrow Transplantation, 22 (3), 393. doi:10.1016/j.bbmt.2015.11.917
Peer Reviewed verified by ORBi

Grégoire, C., Beguin, Y., Hannon, M., DUBOIS, S., BAUDOUX, E., BRIQUET, A., LECHANTEUR, C., Ehx, G., & Baron, F. (29 January 2016). Umbilical cord mesenchymal stromal cells are superior to bone marrow and adipose tissue-derived mesenchymal stromal cells for the treatment of xenogeneic graft-versus-host disease in mice [Poster presentation]. 31th General Meeting of the Belgian Hematological Society.

Delens, L., SERVAIS, S., Vrancken, L., Ehx, G., Fransolet, G., Hannon, M., DUBOIS, S., Daulne, C., BEGUIN, Y., & Baron, F. (29 January 2016). Salt but not glucocorticoïds enhances Th17 differentiation from naïve T cells in vitro [Poster presentation]. 31st General Annual Meeting of the Belgian Hematological Society, La Hulpe, Belgium.

Ehx, G., Hannon, M., Humblet-Baron, S., DUBOIS, S., Daulne, C., Drion, P., BEGUIN, Y., & BARON, F. (29 January 2016). Immunomodulatory effects of rapamycin in Graft versus Host Disease [Poster presentation]. 31st General Annual Meeting of the Belgian Hematological Society, Bruxelles, Belgium.

Fransolet, G., Ehx, G., SOMJA, J., Delens, L., Hannon, M., DUBOIS, S., Drion, P., CAERS, J., Humblet-Baron, S., Belle, L., DELVENNE, P., BEGUIN, Y., Conteduca, G., & Baron, F. (29 January 2016). Azacytidine and Decitabine prevent experimental sclerodermic chronic graft-versus-host disease [Poster presentation]. 31st general annual meeting of the Belgian Hematological Society, La Hulpe, Belgium.

Delens, L., Servais, S., Hannon, M., Ehx, G., Fransolet, G., DUBOIS, S., Daulne, C., Vrancken, L., Beguin, Y., & Baron, F. (03 December 2015). Revisiting Th17 cell subsets in the setting of allogeneic stem cell transplantation and (cortico-refractory) graft-versus-host disease [Poster presentation]. Journée Télévie 2016, Gembloux, Belgium.

Fransolet, G., Ehx, G., SOMJA, J., Hannon, M., DUBOIS, S., Drion, P., CAERS, J., Humblet-Baron, S., Belle, L., Delvenne, P., BEGUIN, Y., Conteduca, G., & Baron, F. (19 November 2015). L'Azacytidine comme traitement de la maladie du greffon contre l'hôte de type chronique sclérodermique expérimentale [Paper presentation]. 15ème congrès de la Société Française de Greffe de Moelle et de Thérapie Cellulaire, Clermont-Ferrand, France.

Ehx, G., Fransolet, G., de Leval, L., D'Hondt, S., Lucas, S., Hannon, M., Delens, L., DUBOIS, S., Drion, P., BEGUIN, Y., Humblet-Baron, S., & BARON, F. (13 November 2015). Azacytidine prevents experimental xenogeneic graft-versus-host disease without abrogating graft-versus-leukemia effects [Paper presentation]. EORTC Leukemia Group-GIMEMA meeting, Rome, Italy.

HANNON, M., BEGUIN, Y., Ehx, G., SERVAIS, S., SEIDEL, L., Graux, C., Maertens, J., Kerre, T., Daulne, C., de Bock, M., Fillet, M., ORY, A., WILLEMS, E., GOTHOT, A., Humblet-Baron, S., & BARON, F. (15 July 2015). Immune Recovery after Allogeneic Hematopoietic Stem Cell Transplantation following Flu-TBI versus TLI-ATG Conditioning. Clinical Cancer Research, 21 (14), 3131-9. doi:10.1158/1078-0432.CCR-14-3374
Peer Reviewed verified by ORBi

HANNON, M. (2015). Etude de la reconstitution immunitaire après greffe de cellules souches hématopoïétiques : focus sur la fonction thymique et les lymphocytes T régulateurs [Doctoral thesis, ULiège - Université de Liège]. ORBi-University of Liège. https://orbi.uliege.be/handle/2268/182309

BINSFELD, M., Hannon, M., Humblet-Baron, S., Beguin, Y., Baron, F., & CAERS, J. (30 January 2015). Effects of the immunomodulating peptide thymosin alpha 1 in multiple myeloma and immune reconstitution after hematopoietic stem cell transplantation in murine models [Poster presentation]. 30th General Annual Meeting of the Belgian Hematology Society, La Hulpe, Belgium.

Delens, L., SERVAIS, S., Hannon, M., Ehx, G., Fransolet, G., DUBOIS, S., Beguin, Y., & Baron, F. (30 January 2015). Effects of Tocilizumab on Th17 cell differentiation in a humanized mouse model of xenogeneic graft-versus-host disease [Poster presentation]. 30st General Annual Meeting of the Belgian Hematological Society, La Hulpe, Belgium.

Ehx, G.* , Hannon, M.* , BEGUIN, Y., Humblet-Baron, S.* , & BARON, F.*. (2015). Validation of a multicolor staining to monitor phosphoSTAT5 levels in regulatory T-cell subsets. Oncotarget, 6, 43255-43266. doi:10.18632/oncotarget.6486
Peer Reviewed verified by ORBi
* These authors have contributed equally to this work.

Cuende, J., Liénart, S., Dedobbeleer, O., van der Woning, B., De Boeck, G., Stockis, J., Huygens, C., Colau, D., SOMJA, J., Delvenne, P., Hannon, M., Baron, F., Dumoutier, L., Renauld, J.-C., De Haard, H., Saunders, M., Coulie, P., & Lucas, S. (2015). Monoclonal antibodies against GARP/TGF-β1 complexes inhibit the immunosuppressive activity of human regulatory T cells in vivo. Science Translational Medicine, 7, 284ra56. doi:10.1126/scitranslmed.aaa1983
Peer Reviewed verified by ORBi

Binsfeld, M., HANNON, M., Otjacques, E., Humblet-Baron, S., BAUDOUX, E., BEGUIN, Y., BARON, F., & CAERS, J. (2015). Impact of the immunomodulating peptide thymosin alpha 1 on multiple myeloma and immune recovery after hematopoietic stem cell transplantation. Cancer Immunology, Immunotherapy, 64, 989-998. doi:10.1007/s00262-015-1708-2
Peer Reviewed verified by ORBi

SERVAIS, S., Menten-Dedoyart, C., Beguin, Y., SEIDEL, L., Gothot, A., Daulne, C., WILLEMS, E., Delens, L., Humblet-Baron, S., Hannon, M., & Baron, F. (2015). Impact of Pre-Transplant Anti-T Cell Globulin (ATG) on Immune Recovery after Myeloablative Allogeneic Peripheral Blood Stem Cell Transplantation. PLoS ONE, 10 (6), 0130026. doi:10.1371/journal.pone.0130026
Peer Reviewed verified by ORBi

Hannon, M., LECHANTEUR, C., Lucas, S., Somja, J., Seidel, L., Belle, L., Bruck, F., BAUDOUX, E., GIET, O., Chantillon, A.-M., Delvenne, P., Drion, P., Beguin, Y., Humblet-Baron, S., & Baron, F. (17 June 2014). Infusion of clinical-grade enriched regulatory T cells delays experimental xenogeneic graft-versus-host disease. Transfusion, 54 (February), 353-363. doi:10.1111/trf.12279
Peer Reviewed verified by ORBi

Ehx, G., HANNON, M., DUBOIS, S., HALLEUX, A., Belle, L., Drion, P., Beguin, Y., Humblet-Baron, S., & Baron, F. (27 January 2014). Immunomodulatory effects of Rapamycin in xenogeneic GVHD [Poster presentation]. GIGA Day 2014, Liège, Belgium.

Baron, F., Humblet-Baron, S., Ehx, G., SERVAIS, S., HANNON, M., Belle, L., LECHANTEUR, C., BRIQUET, A., GIET, O., BAUDOUX, E., WILLEMS, E., & Beguin, Y. (2014). Thinking out of the box - New approaches to controlling GVHD. Current Hematologic Malignancy Reports, 9, 73-84. doi:10.1007/s11899-013-0187-9
Peer Reviewed verified by ORBi

Binsfeld, M., Beguin, Y., Belle, L., Otjacques, E., HANNON, M., BRIQUET, A., Heusschen, R., Drion, P., Zilberberg, J., Bogen, B., Baron, F., & CAERS, J. (2014). Establishment of a murine graft-versus-myeloma model using allogeneic stem cell transplantation. PLoS ONE, 113764. doi:10.1371/journal.pone.0113764
Peer Reviewed verified by ORBi

Binsfeld, M., BEGUIN, Y., Belle, L., Otjacques, E., HANNON, M., BRIQUET, A., Drion, P., Bogen, B., Baron, F., & CAERS, J. (2014). Establishment of a murine graft-versus-myeloma model using allogeneic stem cell transplantation. Belgian Journal of Hematology.

Belle, L., Ehx, G., SOMJA, J., Binsfeld, M., HANNON, M., CAERS, J., Fransolet, G., BEGUIN, Y., Humblet-Baron, S., & Baron, F. (December 2013). Combination Of Regulatory T Cells and Rapamycin As Treatment For Experimental Chronic Graft-Versus-Host Disease [Poster presentation]. 55th Annual Meeting of the American Society of Hematology.

Belle, L., Ehx, G., SOMJA, J., BINSFELD, M., Hannon, M., Caers, J., Fransolet, G., Beguin, Y., Humblet-Baron, S., & Baron, F. (December 2013). Combination Of Regulatory T Cells and Rapamycin As Treatment For Experimental Chronic Graft-Versus-Host Disease. Blood, 122 (21), 4474.
Peer Reviewed verified by ORBi

Binsfeld, M., BEGUIN, Y., Belle, L., Otjacques, E., HANNON, M., BRIQUET, A., Drion, P., Bogen, B., BARON, F., & CAERS, J. (April 2013). Establishment of a murine graft-versus-myeloma model using allogeneic stem cell transplantation [Poster presentation]. 3rd International Conference "Cancer Immunotherapy and Immunomonitoring (CITIM)", Cracovie, Poland.

Bruck, F.* , Belle, L.* , LECHANTEUR, C., de Leval, L., Hannon, M., DUBOIS, S., CASTERMANS, E., Humblet-Baron, S., Rahmouni, S., Beguin, Y., BRIQUET, A.* , & Baron, F.*. (March 2013). Impact of bone marrow-derived mesenchymal stromal cells on experimental xenogeneic graft-versus-host disease. Cytotherapy, 15 (3), 267-279. doi:10.1016/j.jcyt.2012.09.003
Peer Reviewed verified by ORBi
* These authors have contributed equally to this work.

Belle, L., BINSFELD, M., DUBOIS, S., Hannon, M., Caers, J., BRIQUET, A., MENTEN, C., BEGUIN, Y., Humblet-Baron, S., & Baron, F. (February 2013). Prevention of murine sclerodermatous chronic graft-versus-host disease by Rapamycin. Biology of Blood and Marrow Transplantation, 19, 317.
Peer Reviewed verified by ORBi

Belle, L., Binsfeld, M., HANNON, M., CAERS, J., BRIQUET, A., MENTEN, C., BEGUIN, Y., Humblet-Baron, S., & Baron, F. (2013). Combination of Regulatory T Cells Injection with Rapamycin for Treatment of Chronic Graft-versus-Host Disease. Belgian Journal of Hematology.
Peer Reviewed verified by ORBi

De Bock, M., Fillet, M., Hannon, M., Seidel, L., Merville, M.-P., Gothot, A., Beguin, Y., & Baron, F. (2013). Kinetics of IL-7 and IL-15 Levels after Allogeneic Peripheral Blood Stem Cell Transplantation following Nonmyeloablative Conditioning. PLoS ONE, 8 (2), 55876. doi:10.1371/journal.pone.0055876
Peer Reviewed verified by ORBi

Belle, L., Binsfeld, M., Dubois, S., Hannon, M., CAERS, J., BRIQUET, A., MENTEN, C., BEGUIN, Y., Humblet-Baron, S., & BARON, F. (2013). Prevention of murine sclerodermatous chronic graft-versus-host disease by Rapamycin [Poster presentation]. BMT Tandem Meetings (ASBMT), Salt Lake City, United States.

Hannon, M., LECHANTEUR, C., Somja, J., Lucas, S., Belle, L., Bruck, F., Baudoux, E., Beguin, Y., Humblet-Baron, S., & Baron, F. (2013). Infusion of CliniMACS (Myltenyi Biotec) Enriched Regulatory T Cells Delays Experimental Xenogeneic Graft-versus-Host Disease. Belgian Journal of Hematology, Abstracts book (Supplement of 28th General Meeting of the Belgian Hematological Society), 15.

Belle, L., Binsfeld, M., Hannon, M., CAERS, J., BRIQUET, A., MENTEN, C., Beguin, Y., Humblet-Baron, S., & BARON, F. (2013). Combination of Regulatory T Cells Injection with Rapamycin for Treatment of Chronic Graft-versus-Host Disease [Paper presentation]. 28th General Meeting of the Belgian Hematological Society.

Binsfeld, M., Otjacques, E., Hannon, M., DUBOIS, S., Beguin, Y., Baron, F., & CAERS, J. (2013). The Immunomodulating Peptide Thymosin Alpha 1 Has no Effect on Multiple Myeloma Evolution and on Immune Reconstitution. Belgian Journal of Hematology, Abstracts book (Supplement of 28th General Meeting of the Belgian Hematological Society), 41.

Hannon, M., Humblet-Baron, S., Graux, C., Maertens, J., Kerre, T., Theunissen, K., Daulne, C., Willems, E., Belle, L., Binsfeld, M., Gothot, A., Beguin, Y., & Baron, F. (2013). Comparison of Immune Reconstitution after Hematopoietic Stem Cell Transplantation with Flu-TBI versus TLI-ATG Conditioning. Belgian Journal of Hematology, Abstracts book (Supplement of 28th General Meeting of the Belgian Hematological Society), 38.

Belle, L., BINSFELD, M., Dubois, S., Hannon, M., CAERS, J., BRIQUET, A., MENTEN, C., Beguin, Y., Humbelt-Baron, S., & BARON, F. (April 2012). Rapamycin prevents experimental sclerodermatous chronic graft-versus-host disease in mice. Bone Marrow Transplantation, 47 Suppl 1.
Peer Reviewed verified by ORBi

SERVAIS, S., Hannon, M., Daulne, C., Gothot, A., Beguin, Y., & Baron, F. (February 2012). Longitudinal Monitoring of Immune Reconstitution after Allogeneic Peripheral Blood Stem Cell Transplantation (PBSCT): Impact of T-Cell Depletion of the Graft. Biology of Blood and Marrow Transplantation, 18 (2), 274-S275. doi:10.1016/j.bbmt.2011.12.193
Peer Reviewed verified by ORBi

Belle, L., Binsfeld, M., DUBOIS, S., Hannon, M., CAERS, J., Briquet, A., MENTEN, C., Beguin, Y., Humblet-Baron, S., & Baron, F. (2012). Rapamycin prevents experimental sclerodermatous chronic graft-versus-host disease in mice [Paper presentation]. 38th EBMT Annual Meeting.

MENTEN, C., Castermans, E., Hannon, M., Ormenese, S., Beguin, Y., & Baron, F. (2012). What is the Contribution of Host-Derived CMV Immunity after Allogeneic Transplantation following Non-Myeloablative Conditioning? Haematologica, 97 (Supplement 1), 720.
Peer Reviewed verified by ORBi

MENTEN, C., Castermans, E., Hannon, M., Ormenese, S., Beguin, Y., & Baron, F. (2012). Evidence for Expansion of Host-derived CMV-specific CD8+ T cells after Allogeneic Transplantation with Non-Myeloablative Conditioning. Belgian Journal of Hematology, Abstracts book (Supplement of 27th General Meeting of the Belgian Hematological Society), 16.

Hannon, M., Humblet-Baron, S., Graux, C., Maertens, J., Kerre, T., Theunissen, K., Daulne, C., Willems, E., Belle, L., Binsfeld, M., Gothot, A., Beguin, Y., & Baron, F. (2012). Comparison of Immune Reconstitution after Hematopoietic Stem Cell Transplantation with Flu-TBI versus TLI-ATG Conditioning. Haematologica, 97 (Supplement 1), 180.
Peer Reviewed verified by ORBi

Bruck, F., de Leval, L., Belle, L., LECHANTEUR, C., Hannon, M., BRIQUET, A., Dubois, S., CASTERMANS, E., Humblet-Baron, S., Rahmouni, S., BEGUIN, Y., & BARON, F. (2012). Bone marrow-derived mesenchymal stromal cells failed to prevent experimental xenogeneic graft-versus-host disease [Poster presentation]. Belgian Hematological Society General Annual Meeting.

Binsfeld, M., Belle, L., Hannon, M., Hofgaard, Dubois, S., Otjacques, E., BEGUIN, Y., Bogen, BARON, F., & CAERS, J. (2012). Adaptation of a murine chronic GvH model to study graftversus- myeloma effect after allogeneic transplantation. Bone Marrow Transplantation, 47 (Suppl.1).
Peer Reviewed verified by ORBi

Binsfeld, M., Belle, L., Hannon, M., DUBOIS, S., Otjacques, E., Beguin, Y., Baron, F., & CAERS, J. (2012). Adaptation of a Murine Chronic GVH Model to Study Graft versus Myeloma Effect after Allogeneic Transplantation. Belgian Journal of Hematology, Abstracts book (Supplement of 27th General Meeting of the Belgian Hematological Society), 16.

Belle, L., Binsfeld, M., DUBOIS, S., Hannon, M., CAERS, J., BRIQUET, A., MENTEN, C., Beguin, Y., Humblet-Baron, S., & Baron, F. (2012). Rapamycin Prevents Experimental Sclerodermatous Chronic Graft-versus-Host Disease in mice [Paper presentation]. 27th General Meeting of the Belgian Hematological Society.

Bruck, F., Baron, F., DUBOIS, S., BRIQUET, A., Hannon, M., Belle, L., MENTEN, C., Beguin, Y., & Humblet-Baron, S. (February 2011). Rapamycin Delays Xenogeneic Acute Graft Versus Host Disease (aGVHD) in Nod/Scid/Il2RγNull (NSG) Mice: Impact of Regulatory T Cells [Poster presentation]. ASBMT meeting 2011. doi:10.1016/j.bbmt.2010.12.535

Bruck, F., BARON, F., Dubois, S., BRIQUET, A., Hannon, M., Belle, L., MENTEN, C., BEGUIN, Y., & Humblet-Baron, S. (2011). The mTor inhibitor rapamycin delays xenogeneic acute graft versus host disease (aGVHD) in NOD/SCID/IL2rgnull mice (NSG): impact of regulatory T cells [Poster presentation]. Belgian Hematological Society Annual General Meeting.

Belle, L., Baron, F., Bruck, F., Hannon, M., Servais, S., Beguin, Y., & BRIQUET, A. (2011). Despite Inhibitory Effects on Normal Hematopoiesis in Vitro, Imatinib and Nilotinib do not Prevent Engraftment of Human CD34+ HSCs in immunodeficient NSG Mice [Poster presentation]. 26th General Meeting of the Belgian Hematological Society.

Bruck, F., BARON, F., Dubois, S., BRIQUET, A., Hannon, M., Belle, L., MENTEN, C., BEGUIN, Y., & Humblet-Baron, S. (2011). Rapamycin delays xenogeneic acute graft-versus-host disease (aGvHD) in NOD/SCID/IL2Rg NULL (NSG) mice: impact of regulatory T cells [Poster presentation]. ASBMT 2011.

Belle, L., Baron, F., Bruck, F., Hannon, M., SERVAIS, S., Beguin, Y., & BRIQUET, A. (2011). Despite inhibitory effects on normal hematopoiesis in vitro, Imatinib and Nilotinib do not prevent engraftment of human CD34+ HSCs in immunodeficient NSG mice. Belgian Journal of Hematology.
Peer Reviewed verified by ORBi

CASTERMANS, E., Hannon, M., Dutrieux, J., Humblet, S., Seidel, L., Cheynier, R., Willems, E., Gothot, A., Vanbellinghen, J.-F., Geenen, V., Sandmaier, B. M., Storb, R., Beguin, Y., & Baron, F. (2011). Thymic recovery after allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning is limited to patients younger than 60 years of age. Haematologica, 96(2), 298-306. doi:10.3324/haematol.2010.029702
Peer Reviewed verified by ORBi

SERVAIS, S., Hannon, M., Daulne, C., Gothot, A., Beguin, Y., & Baron, F. (2011). Longitudinal Monitoring of Immune Reconstitution After Allogeneic Peripheral Blood Stem Cell Transplantation (HSCT): Impact of T Cell Depletion of the Graft. Belgian Journal of Hematology, Abstracts book (Supplement of 26th General Meeting of the Belgian Hematological Society), 31.

Hannon, M., Humblet-Baron, S., Graux, C., Maertens, J., Kerre, T., Daulne, C., Willems, E., Gothot, A., Beguin, Y., & Baron, F. (2011). Comparison of Immune Reconstitution after Non-myeloablative Hematopoietic Cell Transplantation (HCT) with Flu-TBI versus TLI-ATG Conditioning. Belgian Journal of Hematology, Abstracts book (Supplement of 26th General Meeting of the Belgian Hematological Society), 8.

Hannon, M., Castermans, E., Cheynier, R., Seidel, L., Humblet-Baron, S., Willems, E., Gothot, A., Geenen, V., Sandmaier, B., Storb, R., Beguin, Y., & Baron, F. (2010). Thymic Recovery after Allogeneic Hematopoietic Cell Transplantation with non-Myeloablative Conditioning might Be Limited to Patients Younger than 60 Years of Age [Paper presentation]. 26th General Meeting of the Belgian Hematological Society.

Humblet-Baron, S., CASTERMANS, E., Vanbellinghen, J.-F., Hannon, M., Jacobs, N., WILLEMS, E., Ormenese, S., Beguin, Y., & Baron, F. (February 2009). What Is The Role For Regulatory T-Cells After Nonmyeloablative Conditioning? Biology of Blood and Marrow Transplantation, 15 (2), 122-123. doi:10.1016/j.bbmt.2008.12.377
Peer Reviewed verified by ORBi

Castermans, E., Hannon, M., Drion, P., Geenen, V., Beguin, Y., & Baron, F. (2009). Reconstitution du système immunitaire après allogreffe de cellules souches hématopoïétiques. Revue Médicale de Liège, 64 (S1), 2-8.
Peer reviewed

Castermans, E., Hannon, M., Cheynier, R., Seidel, L., Humblet-Baron, S., WILLEMS, E., Corbier, S., Gothot, A., Geenen, V., Sandmaier, B. M., Storb, R. F., Beguin, Y., & Baron, F. (2009). Thymic Recovery After Allogeneic Hematopoietic Cell Transplantation with Nonmyeloablative Conditioning Might Be Limited to Patients Younger Than 60 Years of Age. Blood, 114 (22), 1149.
Peer Reviewed verified by ORBi

Humblet-Baron, S., CASTERMANS, E., Vanbellighen, J.-F., Hannon, M., Jacobs, N., Beguin, Y., & Baron, F. (February 2008). What is the Role for Regulatory T-Cells after Nonmyeloablative conditioning. Biology of Blood and Marrow Transplantation, 14 (2), 136-137. doi:10.1016/j.bbmt.2007.12.383
Peer Reviewed verified by ORBi

Hannon, M. (2007). Etude de la fonction thymique après greffe de cellules souches hématopoïétiques [Master’s dissertation, ULiège - Université de Liège]. ORBi-University of Liège. https://orbi.uliege.be/handle/2268/148860

Contact ORBi